BILLERICA, Mass.--(BUSINESS WIRE)--Sep. 18, 2009-- Bruker Corporation (NASDAQ: BRKR) today announced an underwritten public secondary offering of 12,000,000 shares of its common stock by two members of the Laukien family not involved in the Company’s business. The selling stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock to cover over-allotments, if any. Bruker will not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders in this offering. Goldman, Sachs & Co., J.P. Morgan Securities Inc. and Deutsche Bank Securities Inc. are acting as joint book-running managers of the proposed offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and is effective. Information about the secondary offering is available in the preliminary prospectus supplement filed with the Securities and Exchange Commission on September 18, 2009. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted.

The offering is being made by means of a prospectus and the related preliminary prospectus supplement only. Copies of the prospectus and the related preliminary prospectus supplement can be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, NY 10004, telephone: 866-471-2526, facsimile: 212-902-9316, or by emailing prospectus-ny@ny.email.gs.com; J.P. Morgan Securities Inc., Attn: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, telephone: 718-242-8002; or Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, telephone: 800-503-4611.

ABOUT BRUKER CORPORATION

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Any statements contained in this press release that do not describe historical facts, such as those, among others, relating to the completion, timing and size of the proposed offering, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the preliminary prospectus supplement and accompanying prospectus related to the proposed offering. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Source: Bruker Corporation

Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com